![](/images/graphics-bg.png)
Bladder Cancer Immunotherapy : BCG and Beyond
Joint Authors
Newton, Mark R.
O'Donnell, Michael A.
Askeland, Eric J.
Luo, Yi
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-06-20
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer.
Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response.
While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment.
Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG.
This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10.
American Psychological Association (APA)
Askeland, Eric J.& Newton, Mark R.& O'Donnell, Michael A.& Luo, Yi. 2012. Bladder Cancer Immunotherapy : BCG and Beyond. Advances in Urology،Vol. 2012, no. 2012, pp.1-13.
https://search.emarefa.net/detail/BIM-452470
Modern Language Association (MLA)
Askeland, Eric J.…[et al.]. Bladder Cancer Immunotherapy : BCG and Beyond. Advances in Urology No. 2012 (2012), pp.1-13.
https://search.emarefa.net/detail/BIM-452470
American Medical Association (AMA)
Askeland, Eric J.& Newton, Mark R.& O'Donnell, Michael A.& Luo, Yi. Bladder Cancer Immunotherapy : BCG and Beyond. Advances in Urology. 2012. Vol. 2012, no. 2012, pp.1-13.
https://search.emarefa.net/detail/BIM-452470
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-452470